Biotechnological innovations in the pharmaceutical industry in Poland 2009

Table of Contents

I. Report methodology

II. Executive summary

III. Overview of the Polish market of pharmaceutical biotechnology

• Key events and trends in the biotechnology sector in Poland
  • Key trends and events in 2007-2009
  • Events and trends anticipated for 2009-2011
• Key characteristics of the Polish market of biotechnology in pharmaceutics
• Value of the Polish market of pharmaceutical biotechnology 2003-2011

IV. Biotech firms in Poland

• Foreign investment on the Polish pharmaceutical biotechnology market
• Number and classification of Polish biotech firms
• Overview of the largest biotech firms on the Polish pharmaceutical market
• Biotech companies connected with the pharmaceutical industry

V. Selected biotechnological innovations of the Polish pharmaceutical industry

• Stem cell therapy: Celther
• siRNA-based innovative biotech drug: Celon Pharna
• Modified monoclonal antibody therapy: Mabion
• Tissue engineering and regenerative medicine: Euroimplant
• Innovative vaccines against skin and kidney cancer: Biocontract
• Innovative platform for the development of biotech drugs: Adamed
• Innovation at the point of contact between science and industry: Biotechnology and Antibiotics Institute
• Biotech innovations leading to the development of new pharmaceutical substances
  • Advanced molecular diagnostics for clinical trials: Read-Gene
  • New technologies for the development of biotech drugs: BioCentrum
  • Innovative screening and comparative research to find bioactive compounds: Proteon Pharmaceuticals
  • BioIT as support for the development of innovative drugs: Selvita

VI. Factors material to the development of biotechnology in Poland

• Human resources
• Opinions about biotechnology in medicine
• Legislative environment
  • Key regulations
  • Act on genetically modified organisms
  • Patent law
  • Legislative support for innovation
  • Quality standards in the Polish biotech sector
• Initiatives supporting the development of innovation and technology transfer
  • Science & technology and industrial parks
    • General overview
    • Current tenants from biotechnology in pharmaceutics and related fields in selected technology parks in Poland
  • Clusters
  • EU funding for the development of biotechnology innovations
  • Access to higher risk capital

VII. List of graphs

VIII. List of tables

IX. About PMR

X. Contact PMR

List of graphs

• 1. Value (PLN m) and y-o-y growth of the Polish market of pharmaceutical biotechnology, 2003-2011 12
• 2. Bioton' s revenues (PLN m) and revenue y-o-y change, 2003-2008
• 3. Bioton' s net financial result (PLN m), 2003-2008
• 4. Bioton' s revenues and net financial result (PLN m), Q1 2008 and Q1 2009
• 5. IBSS Biomed' s revenues (PLN m) and y-o-y revenue change in Poland, 1998-2007
• 6. IBSS Biomed' s net profit (PLN m) and net profit y-o-y change in Poland, 1998-2007
• 7. Biomed Lublin' s revenues (PLN m) and revenue y-o-y change in Poland, 1998-2008
• 8. Biomed Lublin' s net financial result (PLN m) in Poland, 1998-2008
• 9. Polfa Tarchomin' s sales value structure, 2007
• 10. Polfa Tarchomin' s domestic sales value structure, 2008
• 11. Polfa Tarchomin' s revenues (PLN m) and revenue y-o-y change, 1998-Q1 2009
• 12. Polfa Tarchomin' s net financial result (PLN m), 1998-Q1 2009
• 13. Percentage shareholdings in Mabion of Poland, 2009
• 14. Euroimplant' s net financial result (PLN' 000) in Poland, 2007-2008
• 15. Biocontract' s financial results (PLN m) in Poland, 2007
• 16. Adamed' s revenues (PLN m) and revenue y-o-y change in Poland, 1999-2008
• 17. Adamed' s net financial result (PLN m), 1999-2008
• 18. Read-Gene' s net financial result (PLN' 000) in Poland, 2005-2009
• 19. Forecast for Read-Gene' s revenue and net profit structure in Poland, 2009
• 20. BioCentrum' s revenues (PLN m) and revenue y-o-y change in Poland, 2004-2007
• 21. BioCentrum' s net profit (PLN' 000) and net profit y-o-y change in Poland, 2004-2007
• 22. Number of candidates to biotechnology and biomedical engineering specialisation in Poland, 2006-2008
• 23. Projected demand for graduates of natural science specialisations in next 5 and 15 years (number of selections of Voivod Labour Offices) in Poland, December 2008
• 24. Assessment of results of use of modern biotechnological methods in Poland
• 25. Poles' opinion on use of biotechnology to produce new drugs and vaccines
• 26. Opinions on the statement “research into drugs and vaccines to be used in biotechnology and genetic engineering comprise a threat to the environment or human life”
• 27. Applications for closed use of GMOs in projects with applications in medicine and pharmaceutics in Poland, 2002-H1 2009
• 28. Number of applications for closed GMO use by biotech firms of the pharmaceutical industry in Poland, 2002-H1 2009

List of tables

• 1. Structure of Bioton Capital Group, 2008
• 2. The most important science and technology parks which have as a priority direction the support of the development of biotechnological companies in Poland, 2009
• 3. Selected biotechnology-related cluster initiatives relevant to the pharmaceutical and related industries in Poland, 2009
• 4. Companies and institutions from the biopharmaceutical and related sectors, which have received financing from the Innovative Economy Operational Programme and project value in Poland, 2009